Radiofrequency ablation effective treatment for inoperable lung cancer

Lung cancer patients who are not candidates for surgery now have another safe and effective treatment option: radiofrequency (RF) ablation, according to a new study published in the April issue of the journal Radiology.

The Brown Medical School and Rhode Island Hospital study showed that RF ablation used to treat early-stage, inoperable cancer resulted in outcomes that were equal to or better than those achieved through external beam radiation (EBT), a decades-old alternative to the surgical removal of cancerous tissue.

“In our study, RF ablation produced meaningful results in terms of both survival and tumor control,” said Damian E. Dupuy, M.D., director of tumor ablation at Rhode Island Hospital and professor of diagnostic imaging at Brown Medical School in Providence. “The best two-year survival rate for early-stage lung cancer using EBT is 51 percent, compared to 57 percent with ablation.”

Lung cancer is a leading cause of death in the United States. The National Cancer Institute estimates that in 2007, more than 213,000 Americans will be diagnosed with lung cancer and more than 160,000 deaths will result from the disease.

Patients with primary lung cancer, in which cancerous cells first develop in the lung, often are of advanced age and have highly diseased lungs and impaired heart function, making them poor candidates for invasive surgery. The same conditions can also make it difficult for patients to be treated with EBT, which directs focused beams of radiation at a tumor to destroy the abnormal cells.

“Conventional EBT therapy involves 33 treatments over a six-week period and can often lead to side effects including radiation pneumonia and the permanent loss of lung tissue,” said Dr. Dupuy. “RF ablation, which uses high-frequency electrical currents to heat and destroy abnormal cells, is performed in a single day as an outpatient procedure, is minimally invasive and has few side effects.”

In his study, Dr. Dupuy and a research team evaluated the outcomes of 153 patients who underwent computed tomography (CT)-guided RF ablation for 189 inoperable lung cancers, including 116 primary lung cancers and 73 metastases to the lung from other cancers. The majority of the patients, who ranged in age from 17 to 94, also suffered from severe cardiopulmonary disease.

The one, two, three, four and five-year survival rates for stage I, non-small cell lung cancer treated with RF ablation were 78 percent, 57 percent, 36 percent, 27 percent and 27 percent, respectively. A recent study reported that patients with similar cancers who underwent conventional EBT had a three-year survival rate of 34 percent.

Patients with colorectal pulmonary metastasis, in which cancer began in the colon and spread to the lung, had a 57 percent five-year survival rate following RF ablation, which is better than some surgical studies.

“It’s important for physicians to know that RF ablation is a treatment option for their sickest and elderly patients,” Dr. Dupuy said.

The study also showed that RF ablation helped control the progression of patients’ tumors. Tumors three centimeters or smaller took an average of 45 months to grow following treatment; tumors larger than three centimeters progressed in an average of 12 months.

“As the means of detecting early-stage lung cancer improves, we will see less invasive treatment options such as ablation replace surgery during our lifetime,” Dr. Dupuy said.

Source: Radiological Society of North America

Related stories:

New technique in treating patients with liver cancer proves effective
Use of multipolar radiofrequency ablation in the treatment of colorectal liver metastases is effective and has a relatively low recurrence rate, according to a recent study conducted by researchers at Charité, Campus Benjamin Franklin in Berlin, Germany.
Radio Waves Fire Up Nanotubes Embedded in Tumors, Destroying Liver Cancer
Cancer cells treated with carbon nanotubes can be destroyed by noninvasive radio waves that heat up the nanotubes while sparing untreated tissue, a research team led by scientists at The University of Texas M.D. Anderson Cancer Center and Rice University has shown in preclinical experiments.
Radio waves fire up nanotubes embedded in tumors, destroying liver cancer
Cancer cells treated with carbon nanotubes can be destroyed by non-invasive radio waves that heat up the nanotubes while sparing untreated tissue, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center and Rice University has shown in preclinical experiments.
First pharmaceutical drug to improve survival amongst patients with advanced hepatocarcinoma
International research involving the University Hospital of the University of Navarra, together with other hospitals in Spain, has shown that Sorafenib, an orally administered pharmaceutical medicine, results in patients with primary hepatocarcinomas (liver tumours) to live 40% more on average compared to those not taking the drug. The study, led by the Barcelona Hospital Clinic, will be shortly published in the New England Journal of Medicine.
Radiofrequency ablation is effective treatment for dysplasia in Barrett's esophagus
Interim results from a nationwide clinical trial led by a University of North Carolina at Chapel Hill researcher suggest that radiofrequency ablation is an effective treatment for dysplasia in people with Barrett’s esophagus, a condition that can lead to deadly gastrointestinal cancer.
MicroRNAs appear essential for retinal health
Retinas in newborn mice appear perfectly fine without any help from tiny bits of genetic material called microRNAs except for one thing — the retinas do not work.
Zebrafish enables cell regeneration studies to help understand, treat human disease
One aquarium fish’s uncanny ability to regenerate essentially any cell type has given scientists a way to mimic cell loss that occurs in diseases such as Parkinson’s and diabetes then watch how the fish make more of them.
Presence of gene mutation helps guide thyroid cancer treatment
A specific gene mutation may be useful in predicting the level of aggression of thyroid cancer and help guide treatment options and follow-up care, according to new study findings.

News discussion:

Medicine & Health news